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Abstract: Systematic reviews and meta-analytic approaches are
widely used in the clinical arena to integrate outcome data from
published studies in a patient population that address a set of related
research hypotheses. The credibility of this line of research is
dependent on how the studies are chosen, how the data are assem-
bled, and how the results are reported. In this brief report, we
provide an overview of the minimum set of reporting requirements
for systematic reviews and meta-analyses based on the Preferred
Reporting Items of Systematic reviews and Meta-Analyses guide-
lines. As with any research, following a set of established guidelines
is essential for quality and consistency of the findings across studies
and for assessment of clinical utility.
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The Cochrane collaboration1 defines systematic review as areview of a clearly formulated question that uses system-
atic and explicit methods to identify, select, and critically
appraise relevant research, and to collect and analyze data
from the studies that are included in the review. A meta-
analysis then uses appropriate statistical methods to assimi-
late the results of the studies included in the systematic
review to address a set of related research hypotheses. Meta-
analysis of published studies uses summary data from the
published studies and, thus, is restricted in its scope (i.e.,
testing new hypotheses for which summary data are not
previously published). A pooled analysis on the other hand
uses individual subject data from the included studies and can
help answer new research hypotheses (if the relevant data are
available and collected in a similar manner). Meta-analyses
of published studies are typically performed when individual
subject data are not readily accessible/available and under a
framework when the findings from the multiple studies are
conflicting or unclear. In such cases, an integration of the
existing outcome data in a relatively quick manner (as op-
posed to a pooled analysis that requires considerably more
effort) becomes important.
As with any published research, the credibility of a
systematic review is dependent on how the studies are cho-
sen, how the data are assembled, and how the results are
reported. Two recent examples of a well-conducted meta-
analysis are as follows: (a) a meta-analysis performed to
understand the effectiveness of low-dose computed tomogra-
phy for lung cancer screening, while awaiting the results from
the prospective definitive randomized trial2 and (b) a meta-
analysis performed to potentially resolve the conflicting data
on the choice of therapy for previously untreated, transplant
ineligible, elderly patients with myeloma, while awaiting the
results from the pooled analysis of individual patient data and
prospective randomized trials.3
Extensive work in the literature in the mid 1980s and
early 1990s demonstrated that the reporting quality of sys-
tematic reviews and the approaches used for meta-analysis
were generally inconsistent and incompletely reported.4,5
Thus, in 1996, the QUality of Reporting of Meta-analyses
Statement was developed by a group of international re-
searchers, which focused on the minimum set of reporting
requirements for systematic reviews and meta-analyses of
randomized controlled trials.6 This guideline was subse-
quently updated in 2009 to incorporate the conceptual and
practical advances in this arena and was renamed Preferred
Reporting Items of Systematic reviews and Meta-Analyses
(PRISMA).7,8 The PRISMA (and previously the QUality of
Reporting of Meta-analyses) guidelines have been adopted as
a minimal standard for publication requirements by several
journals. Although the main focus of the guidelines is on
randomized trials, it can be used as a basis for reporting
systematic reviews of other types of research.7,8
In this brief report, we provide an overview of the
PRISMA guidelines, which includes the PRISMA flow dia-
gram and the PRISMA checklist for systematic reviews and
meta-analysis. We use a hypothetical example to illustrate
some of the concepts. Together, the checklist and the flow
diagram provide the necessary guidance and documentation
essential for conducting and reporting systematic reviews and
meta-analysis.
THE PRISMA APPROACH
The PRISMA flow diagram is a schematic representa-
tion that maps out the number of studies identified, the
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number excluded, and the reasons for exclusions, and the
final number of studies included in the systematic review and
meta-analysis. This is analogous to the CONSORT diagram
that is followed when reporting results from prospective
clinical trials.9 The PRISMA checklist includes a comprehen-
sive list of 27 items that pertain to the content of performing
and reporting a systematic review and meta-analysis. Below
is a synopsis of the main topics that is covered in the
checklist.7,8
a. Title description.
b. Abstract structure and content.
c. Introduction section that clearly outlines the rationale
and the hypothesis for the purported meta-analysis.
d. Methods section, which includes the search criteria,
selection process for studies that are included in the
review, assembly of data, statistical approaches used to
assimilate the results, and assessment of selection
and/or publication bias.
e. Results section that includes a flow diagram for the final
set of studies included and their quality, information on
the individual study characteristics and results, bias
assessment, summary of each outcome analysis with
estimates and confidence intervals (CIs), and subgroup
and/or sensitivity analyses results.
f. Discussion section that summarizes the main findings
and highlights any limitations.
g. Role of any funding source in the systematic review to
assess potential conflict of interest.
Additional considerations in the interpretation of the
findings from a meta-analysis include the weighting scheme
used to adjust for the study size when integrating the results
(with greater weight assigned to [larger] studies that provide
more information) and the between-study heterogeneity. In a
summary meta-analysis, the reasons for such heterogeneity
are likely caused by the differences in (a) the definitions of
the outcome across the individual studies, (b) dosage and
schedule of treatments, (c) inclusion/exclusion criteria for
subjects in the individual studies, etc. In the meta-analysis
by Gopal et al.,2 the heterogeneity in the control arm
(using chest x-ray versus no screening) across the trials
was addressed by doing two separate analyses including all
studies and including only those that used chest x-ray as
the control arm. In the case of Kapoor et al.,3 sensitivity
analyses by leaving out one trial at a time were performed
to more fully capture the impact of the trial level hetero-
geneity on the final conclusions.
HYPOTHETICAL EXAMPLE
Assume that six published reports testing the efficacy of
a control regimen (C) to an experimental regimen (E) to treat
patients with advanced lung cancer were identified using the
Cochrane collaboration recommended optimal search strat-
egy. Table 1 is a summary of the hypothetical outcome data
from the individual studies. As an aside, in instances where
relevant summary statistics are not readily available from the
published articles, the information on observed number of
events and reported p value from the log-rank-test statistic
can be used to derive the point estimates and its associated
standard error (or variance).10 Given the somewhat differing
levels of agreement in the overall survival (OS) outcome for
the optimal treatment (C versus E) in this example, a meta-
analysis of these studies can be conducted to assimilate the
results. Under a random effects model, the summary HR and
the 95% CI would be 1.134 (0.89–1.44; p value: 0.3), thus
suggesting that there is no statistically significant difference
in OS between the treatments. Suppose that the study II
outcomes were 1.5 (1.4–1.6), and 0.001 for the HR (95% CI)
and the variance (log HR), and the variance (log HR) for
studies 5 and 6 were 0.02, then the summary HR and the 95%
CI would be 1.24 (0.99–1.6; p value: 0.06) under a random
effects model, suggesting a trend toward favorable outcome
for the experimental regimen E.
The between-trial heterogeneity in both of the above
scenarios is high, thus requiring additional (sensitivity/sub-
group) analyses to be performed to understand and identify
those studies that contribute to the heterogeneity. In this
example, if studies 5 and 6 are excluded, then the heteroge-
neity across the remaining four trials becomes insignificant,
and the overall HR of 1.4 (p  0.002) shows a statistically
significant improvement in OS for the experimental regimen
over the control regimen. Removal of studies 2, 5, and 6
results in a complete disappearance of heterogeneity and a
much stronger evidence in favor of E.
SUMMARY
The reporting quality of systematic reviews and meta-
analyses has considerable variation, thus limiting the ability
to comprehensively assess the strengths and weaknesses of
the reviews and the clinical utility of the results. A well-
conducted systematic review should be a thorough process of
collecting, reviewing, and presenting all available evidence,
and a well-conducted meta-analysis should use the appropri-
ate statistical techniques to extract and combine data across
studies to produce a summary result. The PRISMA guideline
referenced in this brief report is a recommended standard for
reporting systematic reviews and meta-analyses.
TABLE 1. Data from Six Hypothetical Trials with Similar
Sample Size in Advanced Lung Cancer Comparing C
(Control Regimen) vs. E (Experimental Regimen)
Study
Number
Overall Survival
Hazard Ratio
(C vs. E) (95% CI)
Variance
(Log HR)
I 1.7 (1.29–2.24) 0.02
II 1.04 (0.74–1.46) 0.03
III 1.5 (1.07–2.11) 0.03
IV 1.3 (0.99–1.72) 0.02
V 0.9 (0.78–1.03) 0.005
VI 0.8 (0.75–0.85) 0.001
CI, confidence interval; HR, hazard ratio.
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